Drug General Information
Drug ID	D0H9DA
Former ID	DIB003378
Drug Name	AZD6738
Indication	Chronic lymphocytic leukaemia [ICD10:C91]		Phase 1	[524454]
Company	Astrazeneca; eagle pharmaceuticals
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	Serine threonine protein kinase ATR	Target Info	Inhibitor	[532880], [532980], [550504]
KEGG Pathway	Fanconi anemia pathway
	Cell cycle
	p53 signaling pathway
	HTLV-I infection
PANTHER Pathway	p53 pathway
	p53 pathway feedback loops 2
Pathway Interaction Database	Fanconi anemia pathway
	ATR signaling pathway
	Signaling events mediated by TCPTP
	Circadian rhythm pathway
	BARD1 signaling events
	p53 pathway
Reactome	Meiotic synapsis
	Activation of ATR in response to replication stress
	Regulation of HSF1-mediated heat shock response
	HDR through Single Strand Annealing (SSA)
	Processing of DNA double-strand break ends
	Presynaptic phase of homologous DNA pairing and strand exchange
	G2/M DNA damage checkpoint
WikiPathways	DNA Damage Response
	Meiotic Synapsis
	Prostate Cancer
	Integrated Breast Cancer Pathway
	Integrated Cancer pathway
	Cell Cycle
	Cell Cycle Checkpoints
	miRNA Regulation of DNA Damage Response
References
Ref 524454	ClinicalTrials.gov (NCT01955668) AZD6738 First Time in Patient Multiple Ascending Dose Study. U.S. National Institutes of Health.
Ref 532880	Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970. Oncotarget. 2014 Jul 30;5(14):5674-85.
Ref 532980	ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses. Cancer Res. 2014 Dec 1;74(23):6968-79.
Ref 550504	National Cancer Institute Drug Dictionary (drug id 754022).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.